S&P 500   3,147.04 (+0.95%)
DOW   28,013.00 (+1.21%)
QQQ   204.87 (+1.01%)
AAPL   270.20 (+1.74%)
MSFT   151.53 (+1.07%)
NVDA   212.24 (+1.68%)
MU   48.10 (+3.17%)
BABA   201.48 (+0.74%)
GE   11.01 (+2.04%)
TSLA   335.61 (+1.59%)
T   38.23 (+0.10%)
F   9.00 (+0.78%)
NFLX   307.23 (+1.44%)
BAC   33.74 (+1.93%)
DIS   147.89 (+0.30%)
S&P 500   3,147.04 (+0.95%)
DOW   28,013.00 (+1.21%)
QQQ   204.87 (+1.01%)
AAPL   270.20 (+1.74%)
MSFT   151.53 (+1.07%)
NVDA   212.24 (+1.68%)
MU   48.10 (+3.17%)
BABA   201.48 (+0.74%)
GE   11.01 (+2.04%)
TSLA   335.61 (+1.59%)
T   38.23 (+0.10%)
F   9.00 (+0.78%)
NFLX   307.23 (+1.44%)
BAC   33.74 (+1.93%)
DIS   147.89 (+0.30%)
S&P 500   3,147.04 (+0.95%)
DOW   28,013.00 (+1.21%)
QQQ   204.87 (+1.01%)
AAPL   270.20 (+1.74%)
MSFT   151.53 (+1.07%)
NVDA   212.24 (+1.68%)
MU   48.10 (+3.17%)
BABA   201.48 (+0.74%)
GE   11.01 (+2.04%)
TSLA   335.61 (+1.59%)
T   38.23 (+0.10%)
F   9.00 (+0.78%)
NFLX   307.23 (+1.44%)
BAC   33.74 (+1.93%)
DIS   147.89 (+0.30%)
S&P 500   3,147.04 (+0.95%)
DOW   28,013.00 (+1.21%)
QQQ   204.87 (+1.01%)
AAPL   270.20 (+1.74%)
MSFT   151.53 (+1.07%)
NVDA   212.24 (+1.68%)
MU   48.10 (+3.17%)
BABA   201.48 (+0.74%)
GE   11.01 (+2.04%)
TSLA   335.61 (+1.59%)
T   38.23 (+0.10%)
F   9.00 (+0.78%)
NFLX   307.23 (+1.44%)
BAC   33.74 (+1.93%)
DIS   147.89 (+0.30%)
Log in

OTCMKTS:EAPH - Easton Pharmaceuticals Stock Price, Forecast & News

$0.0026
0.00 (0.00 %)
(As of 11/19/2019)
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.01
Volume569,590 shs
Average Volume3.24 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Easton Pharmaceuticals Inc., a specialty pharmaceutical company, designs, develops, and markets various topically delivered drugs and therapeutic health care products. Its products include Nauseasol, a motion sickness gel; Skin Renou HA, an anti-aging wrinkle cream using hyaluronic acid, which keeps the skin smooth; Kenestrin Gel used for arthritis, knees, elbows, shoulders, wrist, and back pain; Viorra, a hormone free, non-toxic, and topical gel that improves sexual functioning of women; and female sexual arousal disorder drug. The company is also developing XILIVE, an early stage cancer drug. In addition, it is involved in the medical marijuana business. The company was formerly known as LAM Industries, Inc. and changed its name to Easton Pharmaceuticals Inc. in March 2010. Easton Pharmaceuticals Inc. was founded in 1997 and is based in Toronto, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:EAPH
CUSIPN/A
CIKN/A
Phone416-619-0291

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive EAPH News and Ratings via Email

Sign-up to receive the latest news and ratings for EAPH and its competitors with MarketBeat's FREE daily newsletter.


Easton Pharmaceuticals (OTCMKTS:EAPH) Frequently Asked Questions

What is Easton Pharmaceuticals' stock symbol?

Easton Pharmaceuticals trades on the OTCMKTS under the ticker symbol "EAPH."

Has Easton Pharmaceuticals been receiving favorable news coverage?

Press coverage about EAPH stock has been trending positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Easton Pharmaceuticals earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Easton Pharmaceuticals.

Who are some of Easton Pharmaceuticals' key competitors?

What other stocks do shareholders of Easton Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Easton Pharmaceuticals investors own include 22nd Century Group (XXII), Medmen Enterprises (MMNFF), Canopy Growth (CGC), CannaRoyalty (ORHOF), Emerald Health Therapeutics (EMHTF), GreenGro Technologies (GRNH), KushCo (KSHB), mCig (MCIG), Tilray (TLRY) and Aurora Cannabis (ACBFF).

Who are Easton Pharmaceuticals' key executives?

Easton Pharmaceuticals' management team includes the folowing people:
  • Mr. Evan Karras, CEO, Pres, Sec. & Director
  • Mr. Nunzio J. Valerie Jr., CFO & Director (Age 57)
  • Mr. Vince Demasi, COO & Director
  • Dr. Lilla Albert Ph.D., Chief Marketing and Technology Officer
  • Ms. Elena Milantoni, Director of Fin. and Admin. (Age 49)

How do I buy shares of Easton Pharmaceuticals?

Shares of EAPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Easton Pharmaceuticals' stock price today?

One share of EAPH stock can currently be purchased for approximately $0.00.

What is Easton Pharmaceuticals' official website?

The official website for Easton Pharmaceuticals is http://www.eastonpharmaceuticalsinc.com/.

How can I contact Easton Pharmaceuticals?

The company can be reached via phone at 416-619-0291.


MarketBeat Community Rating for Easton Pharmaceuticals (OTCMKTS EAPH)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  131
MarketBeat's community ratings are surveys of what our community members think about Easton Pharmaceuticals and other stocks. Vote "Outperform" if you believe EAPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EAPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel